Zacks Investment Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Zacks Investment Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$623K	Buy	+36,687	New	+$586K	﹤0.01%	482

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zacks Investment Management's AUPH Position: Q2 2026 in Review

Zacks Investment Management opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 36,687 shares worth $623K. The stake represents ﹤0.01% of the portfolio and ranks #482 among its holdings.

281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Zacks Investment Management held 36,687 shares of Aurinia Pharmaceuticals worth $623K as of Q2 2026.
Aurinia Pharmaceuticals was a new Zacks Investment Management position in Q2 2026.
Aurinia Pharmaceuticals made up ﹤0.01% of Zacks Investment Management's portfolio in Q2 2026, its #482 holding.
281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Zacks Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.